The DOI matches its Crossref record; the references it cites are not checked yet.
Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes
Open accessAbstract
OBJECTIVE: This study investigated the safety and efficacy of sitagliptin (Januvia) for the inpatient management of type 2 diabetes (T2D) in general medicine and surgery patients. RESEARCH DESIGN AND METHODS: In this pilot, multicenter, open-label, randomized study, patients (n = 90) with a known history of T2D treated with diet, oral antidiabetic agents, or low total daily dose of insulin (≤0.4 units/kg/day) were randomized to receive sitagliptin alone or in combination with glargine insulin (glargine) or to a basal bolus insulin regimen (glargine and lispro) plus supplemental (correction) doses of lispro. Major study outcomes included differences in daily blood glucose (BG), frequency of treatment failures (defined as three or more consecutive BG >240 mg/dL or a mean daily BG >240 mg/dL), and hypoglycemia between groups. RESULTS: Glycemic control improved similarly in all treatment groups. There were no differences in the mean daily BG after the 1st day of treatment (P = 0.23), number of readings within a BG target of 70 and 140 mg/dL (P = 0.53), number of BG readings >200 mg/dL (P = 0.23), and number of treatment failures (P > 0.99). The total daily insulin dose and number of insulin injections were significantly less in the sitagliptin groups compared with the basal bolus group (both P < 0.001). There were no differences in length of hospital stay (P = 0.78) or in the number of hypoglycemic events between groups (P = 0.86). CONCLUSIONS: Results of this pilot indicate that treatment with sitagliptin alone or in combination with basal insulin is safe and effective for the management of hyperglycemia in general medicine and surgery patients with T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have compared different basal insulin formulations, including glargine U100, insulin detemir U100, glargine U300, and degludec U100, with similar glycemic control results.92,107,1343–1346”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1346]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 28 · Cited by 166
Research works printed but not linked: 1
- Seley, 2009, Position statement: inpatient glycemic control, Diabetes Educ, 35, 65
Metadata
- Authors
- Umpierrez, G. E., Gianchandani, R., Smiley, D., Jacobs, S., Wesorick, D. H., Newton, C., Farrokhi, F., Peng, L., Reyes, D., Lathkar-Pradhan, S., & Pasquel, F.
- Affiliations
- Emory University (US)
- Michigan Medicine (US)
- Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan
- Corresponding author
- Umpierrez, Guillermo E.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-10-15
- Volume
- 36
- Issue
- 11
- Pages
- 3430-3435
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3816910
- OpenAlex
- W2099853060
- Cited by
- 166
- References
- 28
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 10 · 2023: 13 · 2022: 13 · 2021: 13 · 2020: 22 · 2019: 15 · 2018: 16 · 2017: 15 · 2016: 15 · 2015: 12 · 2014: 9 · 2013: 1
- FWCI
- 9.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000454)
- National Center for Research Resources (UL1RR025008)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- sitagliptin, type 2 diabetes, inpatient management, hyperglycemia, basal insulin, glargine, multiple daily insulin injections, glycemic control, hypoglycemia, insulin dose reduction, surgical patients, medical patients
- MeSH terms
- Sitagliptin Phosphate, Insulin Glargine, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Humans, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents, Inpatients, Insulin, Male, Middle Aged, Pyrazines, Triazoles, Insulin, Long-Acting, Insulin Lispro
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/dc13-0277
- The paper
- Umpierrez, G. E., Gianchandani, R., Smiley, D., Jacobs, S., Wesorick, D. H., Newton, C., Farrokhi, F., Peng, L., Reyes, D., Lathkar-Pradhan, S., & Pasquel, F. (2013). Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/dc13-0277
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.